glp 1 for type 2 diabetes Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide analogues in adults with mellitus glycaemic control GLP-1 receptor agonism: a transformative

Conclusion With continuous breakthroughs in oral GLP-1 therapies, oral GLP-1 drug development trends are driving a new growth cycle in the global metabolic disease treatment landscape

YL: Writing review & editing, Writing original draft

Originally discovered for its regenerative properties, it has since gained attention within medical research and sports science for its prospective abilities to aid recovery and promote healing

To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data